NRX Pharmaceuticals, Inc. (NRXP) stock
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.80+0.35 (+14.29%)
Close on Nov 18, 2026Market cap $121.23MP/E –Yield –
NRX Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
NRX Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$19.77M. For fiscal 2025 it was -$14.11M. The highest annual figure on record is -$473.19K in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$14.11M | – |
| FY2024 | Dec 31, 2024 | -$10.64M | – |
| FY2023 | Dec 31, 2023 | -$21.66M | – |
| FY2022 | Dec 31, 2022 | -$39.76M | – |
| FY2021 | Dec 31, 2021 | -$37.70M | – |
| FY2020 | Dec 31, 2020 | -$2.27M | – |
| FY2019 | Dec 31, 2019 | -$792.73K | – |
| FY2018 | Dec 31, 2018 | -$473.19K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.30M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.10M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.56M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.32M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.27M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.28M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.01M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.02M | – |
| Q4 FY2020 | Dec 31, 2020 | -$406.71K | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.13M | – |
| Q2 FY2020 | Jun 30, 2020 | -$651.84K | – |
| Q1 FY2020 | Mar 31, 2020 | -$76.43K | – |
| Q4 FY2019 | Dec 31, 2019 | -$262.07K | – |
| Q3 FY2019 | Sep 30, 2019 | -$52.31K | – |
| Q2 FY2019 | Jun 30, 2019 | -$180.65K | – |
| Q1 FY2019 | Mar 31, 2019 | -$297.70K | – |
| Q4 FY2018 | Dec 31, 2018 | -$70.88K | – |
| Q3 FY2018 | Sep 30, 2018 | -$67.40K | – |
| Q2 FY2018 | Jun 30, 2018 | -$137.08K | – |
| Q1 FY2018 | Mar 31, 2018 | -$197.82K | – |
| Q4 FY2017 | Dec 31, 2017 | -$135.81K | – |
See a number that looks wrong?